Institution
Kanagawa Prefectural Hospital Organization
Recent research
- Health & MedicineOpen access
Neoadjuvant chemotherapy with gemcitabine and S-1 (NAC-GS) is a conditionally recommended treatment for resectable pancreatic ductal adenocarcinoma (PDAC) in Japan. However, therapeutic efficacy remains limited in a subset of patients who lose surgical opportunities due to tumor...
- Health & MedicineOpen access
Abstract Background In the Phase 3 DeLLphi-304 trial, tarlatamab significantly improved overall survival (OS) over chemotherapy for small-cell lung cancer (SCLC) progressed after platinum-based chemotherapy. We report efficacy and safety in the Japanese subpopulation. Methods Pat...
- Health & MedicineOpen access
ABSTRACT Superficial non‐ampullary duodenal epithelial tumors (SNADETs) are increasingly treated with endoscopic resection. Although conventional thermal techniques are effective, the thin duodenal wall and distinctive anatomy have driven interest in cold resection techniques tha...
- Society & EconomicsOpen access
Background Esports (competitive and organised video gaming) may enhance physical and cognitive health in older adults. The aim of this study was to examine the feasibility and effects of a multicomponent program incorporating esports on physical and cognitive function in communit...
- Health & Medicine
The randomized phase II DEEPER trial (jRCTs061180022) previously reported superior depth of response with modified 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (m-FOLFOXIRI) plus cetuximab versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer (m...
- Health & MedicineOpen access
Abstract Topic Esophageal Cancer: Surgical Treatment of Esophageal Cancer – technique Background Esophageal cancer frequently metastasizes to superior mediastinal lymph, necessitating thorough lymphadenectomy. However, the Japanese National Cancer Database reports significantly h...
- Health & MedicineOpen access
Platinum plus etoposide combined with programmed death-ligand 1 (PD-L1) inhibitors is the standard first-line therapy for patients with advanced small-cell lung cancer (SCLC). However, reliable prognostic biomarkers are yet to be identified. The lactate dehydrogenase-to-lymphocyt...